Literature DB >> 28918096

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.

Ankit C Borisa1, Hardik G Bhatt2.   

Abstract

Aurora kinase belongs to serine/threonine kinase family which controls cell division. Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer regime because of its important role during cell division. Here, in this review, we have carried out exhaustive study of various synthetic molecules reported as Aurora kinase inhibitors and developed as lead molecule at various stages of clinical trials from its discovery in 1995 to till date. We reported details of small molecules, specifically inhibiting all 3 types of Aurora kinases, which includes extensive literature search in various database like various scientific journals, patents, scifinder and PubMed database, internet resources, books, etc. IC50 values of tumor growth inhibition, in-vitro and in-vivo activity along with clinical trial data. Here, we took efforts to describe essence of Aurora kinase and its inhibition which could be used to develop anti-mitotic drug for the treatment of cancer. In conclusion, we also discuss future perspectives for development of novel inhibitors and their scope in drug development process.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aurora kinase; Aurora-A; Aurora-B; Aurora-C; INCENP; Small molecule inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28918096     DOI: 10.1016/j.ejmech.2017.08.045

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  44 in total

1.  A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Authors:  Michael Carducci; Montaser Shaheen; Ben Markman; Sara Hurvitz; Daruka Mahadevan; Dusan Kotasek; Oscar B Goodman; Erik Rasmussen; Vincent Chow; Gloria Juan; Gregory R Friberg; Erick Gamelin; Florian D Vogl; Jayesh Desai
Journal:  Invest New Drugs       Date:  2018-07-07       Impact factor: 3.850

2.  [Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro].

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhixian Chen; Wei Huang; Jiangyuan Huang; Shufeng Zhao; Xinfa Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-12-30

3.  Deploying Kinase Inhibitors to Study Pediatric Gliomas.

Authors:  Benjamin T Himes; Liang Zhang; David J Daniels
Journal:  Methods Mol Biol       Date:  2022

4.  Aurora B: A new promising therapeutic target in cancer.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2018-05

5.  Haploinsufficient tumor suppressor Tip60 negatively regulates oncogenic Aurora B kinase.

Authors:  Arnab Bose; Surabhi Sudevan; Vinay J Rao; Hiroki Shima; Arun Kumar Trivedi; Kazuhiko Igarashi; Tapas K Kundu
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

6.  Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells.

Authors:  Andrea Gutierrez Maria; Kleiton Silva Borges; R C P Lira; Carolina Hassib Thomé; Annabel Berthon; Ludivine Drougat; Katja Kiseljak-Vassiliades; Margaret E Wierman; Fabio R Faucz; Vitor Marcel Faça; Luiz Gonzaga Tone; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2021-03-11       Impact factor: 4.102

Review 7.  Cell cycle control in cancer.

Authors:  Helen K Matthews; Cosetta Bertoli; Robertus A M de Bruin
Journal:  Nat Rev Mol Cell Biol       Date:  2021-09-10       Impact factor: 94.444

8.  CDK6 Is a Therapeutic Target in Myelofibrosis.

Authors:  Avik Dutta; Dipmoy Nath; Yue Yang; Bao T Le; Golam Mohi
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

9.  Targeting glioma cells by antineoplastic activity of reversine.

Authors:  Camila Hirakata; Keli Lima; Bruna Oliveira De Almeida; Lívia Bassani Lins De Miranda; Katharine Gurgel Dias Florêncio; Luciana Costa Furtado; Leticia Veras Costa-Lotufo; João Agostinho Machado-Neto
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

10.  Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant Staphylococcus aureus.

Authors:  Di Li; Rammohan R Yadav Bheemanaboina; Narsaiah Battini; Vijai Kumar Reddy Tangadanchu; Xian-Fu Fang; Cheng-He Zhou
Journal:  Medchemcomm       Date:  2018-08-01       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.